Eisai Co., Ltd. (ESALF)
OTCMKTS
· Delayed Price · Currency is USD
28.76
0.00 (0.00%)
Apr 23, 2025, 4:00 PM EDT
Eisai Revenue
Eisai had revenue of 216.14B JPY in the quarter ending December 31, 2024, with 21.63% growth. This brings the company's revenue in the last twelve months to 791.66B, up 5.63% year-over-year. In the fiscal year ending March 31, 2024, Eisai had annual revenue of 741.75B, down -0.36%.
Revenue (ttm)
791.66B JPY
Revenue Growth
+5.63%
P/S Ratio
1.59
Revenue / Employee
71.53M JPY
Employees
11,067
Market Cap
8.01B USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 741.75B | -2.65B | -0.36% |
Mar 31, 2023 | 744.40B | -11.82B | -1.56% |
Mar 31, 2022 | 756.23B | 110.28B | 17.07% |
Mar 31, 2021 | 645.94B | -49.68B | -7.14% |
Mar 31, 2020 | 695.62B | 52.79B | 8.21% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
SS Innovations International | 20.65M |
Endo Inc. | 1.76B |
Veradigm | 588.02M |
Elite Pharmaceuticals | 70.00M |
Northwest Biotherapeutics | 1.38M |
Glass House Brands | 200.90M |
BioStem Technologies | 301.83M |
American Oncology Network | 1.76B |
Eisai News
- 8 days ago - Europe Approves Eisai-Biogen's Alzheimer's Drug 'Under Strict Conditions' After Initial Negative Opinion - Benzinga
- 9 days ago - Biogen/ Eisai win EU approval for Alzheimer’s therapy - Seeking Alpha
- 9 days ago - EU authorizes Eisai-Biogen's drug for treatment of early Alzheimer's disease - Reuters
- 22 days ago - Japanese Stocks Rise With Market Focused on U.S. Trade News - Barron's
- 7 weeks ago - LEQEMBI Market Sales Reflect Growing Confidence in Disease-Modifying Alzheimer's Treatments| DelveInsight - Benzinga
- 7 weeks ago - EU regulator not updating opinion on Eisai-Biogen's Alzheimer's drug - Reuters
- 2 months ago - Eisai: Will Have No Problem Hitting Leqembi Forecasts - Seeking Alpha
- 2 months ago - Q3 2025 Eisai Co Ltd Earnings Presentation Transcript - GuruFocus